5.62

6.24% 0.33

After Hours: 5.62

Olema Pharmaceuticals Inc (OLMA)

Overview News Price History Option Chain Financials Discussions Forecast

Olema Pharmaceuticals Inc stock is traded at $5.62, with a volume of 983.18K. It is up +6.24% in the last 24 hours and up +68.77% over the past month. Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Previous Close:

$5.29

Open:

$5.35

24h Volume:

983.18K

Relative Volume:

1.06

Market Cap:

$335.65M

Revenue:

Net Income/Loss:

$-96.66M

P/E Ratio:

-2.614

EPS:

-2.15

Net Cash Flow:

$-83.73M

1W Performance:

+14.46%

1M Performance:

+68.77%

6M Performance:

-51.64%

1Y Performance:

-44.19%

1-Day Range:

$5.33

$5.735

1-Week Range:

$4.66

$5.735

52-Week Range:

$2.86

$16.62

Olema Pharmaceuticals Inc Stock (OLMA) Company Profile

Name

Olema Pharmaceuticals Inc

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

(415) 651-3316

Address

780 BRANNAN STREET, SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2025-03-18

Latest SEC Filings

OLMA's Discussions on Twitter

Compare OLMA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OLMA Olema Pharmaceuticals Inc	5.62	335.65M	0	-96.66M	-83.73M	-2.15
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-24	Initiated	Goldman	Buy
Jan-30-24	Initiated	Citigroup	Buy
Jul-21-23	Initiated	Oppenheimer	Outperform
May-05-23	Initiated	CapitalOne	Overweight
Feb-22-23	Initiated	Credit Suisse	Outperform
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight
Dec-14-20	Initiated	Jefferies	Buy

View All

Olema Pharmaceuticals Inc Stock (OLMA) Latest News

May 02, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News - GuruFocus

May 02, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 02, 2025

Breast Cancer Drug Developer Olema Awards 104,400 Stock Options to Key New Hires - Stock Titan

May 02, 2025

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Legal & General Group Plc - Defense World

May 02, 2025

May 01, 2025

A look into Olema Pharmaceuticals Inc (OLMA)’s deeper side - Sete News

May 01, 2025

Renaissance Technologies LLC Has $917,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World

May 01, 2025

Apr 30, 2025

Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight - GlobeNewswire Inc.

Apr 30, 2025

Can you now get a good deal on Olema Pharmaceuticals Inc’s shares? - uspostnews.com

Apr 30, 2025

Olema Pharmaceuticals' (OLMA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Apr 30, 2025

Apr 29, 2025

Walleye Capital LLC Invests $391,000 in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat

Apr 29, 2025

Financial Snapshot: Analyzing Olema Pharmaceuticals Inc (OLMA)’s Key Ratio Metrics - DWinneX

Apr 29, 2025

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by JPMorgan Chase & Co. - Defense World

Apr 29, 2025

Olema Pharmaceuticals’ (OLMA) Buy Rating Reaffirmed at HC Wainwright - Defense World

Apr 29, 2025

Apr 28, 2025

Market Recap Check: Olema Pharmaceuticals Inc (OLMA)’s Negative Finish at 3.76, Up/Down -8.52 - DWinneX

Apr 28, 2025

Silverarc Capital Management LLC Reduces Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat

Apr 28, 2025

Apr 27, 2025

Avoro Capital Advisors LLC Takes $9.63 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat

Apr 27, 2025

Apr 26, 2025

Geode Capital Management LLC Decreases Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World

Apr 26, 2025

Bain Capital Life Sciences Investors LLC Invests $43.55 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat

Apr 26, 2025

Apr 25, 2025

Olema Pharmaceuticals Says OP-3136 Molecule Shows Anti-Tumor Activity in Preclinical Models - marketscreener.com

Apr 25, 2025

Olema Oncology Announces New Preclinical Data for OP-3136 - GlobeNewswire

Apr 25, 2025

Cancer Breakthrough: New Drug OP-3136 Achieves 28-Day Tumor Regression in Multiple Cancer Types - Stock Titan

Apr 25, 2025

Apr 24, 2025

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Update - MarketBeat

Apr 24, 2025

Financial Analysis: Olema Pharmaceuticals Inc (OLMA)’s Ratios Unveil Key Insights - DWinneX

Apr 24, 2025

Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet - Yahoo Finance

Apr 24, 2025